Mobile website
Archive > Volume 24 Issue 9 > 2017,24(9):966-971. DOI:10.3872/j.issn.1007-385X.2017.09.007 Prev Next
Basic Research
Clinical effectiveness of dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of locally advanced unresectable or metastatic gastric adenocarcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the clinical efficacy and safety of autogenous dendritic cell-cytokine induced killer (DC-CIK) cell combined with chemotherapy in treatment of locally advanced unresectable or metastatic gas-tric adenocarcinoma. Methods: In this randomized and controlled trial, 32 patients with advanced gastric adenocar-cinoma, who were hospitalized in the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Med-ical Sciences during November, 2014 to July, 2016, were divided into the combined treatment group (16 cases for DC-CIK cell combined chemotherapy) and the mono-drug group (16 cases for chemotherapy alone) by the ration of 1∶1. The baseline data of two groups were comparable. Peripheral blood mononuclear cells (PBMCs) were collected from patients of both groups to obtain DC and CIK cells via in vitro culture. The mono-drug group was treated with SOX or SP chemotherapy regimen, while combined treatment group was treated with referred chemotherapy com-bined with DC-CIK cells. The adverse reactions, curative effect, peripheral blood T cell subsets and qualities of life of the patients in two groups were compared and analyzed. Results: There was no significant difference in T cell subsets in the combined treatment group compared with pre-treatment value (P>0.05); However, the post-treatment percentage of CD3 + , CD3 + CD4 + , CD3 + CD8 + and CD3 - CD56 + in peripheral blood decreased significantly in the mono-drug group(P<0.05). The disease control rate and progression free survival in combined treatment group were signif-icantly increased compared to the mono-drug group (87.5% vs 50%，8.9 months vs 4.4 months, respectively, all P<0.05). There was no significant difference in overall survival between two groups (18.0 months vs 14.0 months, P>0.05). After treatment, compared with the mono-drug group, fatigue and insomnia caused by chemotherapy or dis-ease itself in the combined treatment group was significantly improved (P<0.05). No severe toxicity was observed after infusion of DC-CIK cells. Conclusion: The treatment of DC-CIK cells combined with chemotherapy can obvi-ously optimize the immune function and improve the life quality of the patients with locally advanced unresectable or metastatic gastric adenocarcinoma; the combined treatment improved clinical efficacy and did not bring any obvi-ous adverse reactions.
Keywords:
Project Supported:
Project supported by the Beijing Science and Technology Plan of Beijing (No.Z14010101101)
Clc Number:
